miR-874 targets both AQP1 and AQP3 in several pathologies, mitigating inflammation and myocardial disfunction in sepsis by inhibiting AQP1 [179], and downregulating AQP3 expression in various cancers including gastric cancer [180], pancreatic ductal adenocarcinoma [28] and non-small cell lung cancer (NSCLC) [181], impairing tumor development. Here, AQP1 is linked to gastric cancer.